Actavis loses Atelvia patent fight; CA high court hears pay-for-delay case;

@FiercePharma: #ICYMI yesterday: $BMY leapfrogs Merck with Opdivo approval in lung cancer. Story | Follow @FiercePharma

@EricPFierce: MS Pharma in Jordan gets $30M development loan to expand its drug manufacturing. News | Follow @EricPFierce

@CarlyHFierce: J&J, Merck to advance #Ebola vaccines in Africa, but their fate rests in WHO's hands. More | Follow @CarlyHFierce

> Actavis ($ACT) lost an intellectual property fight over its osteoporosis med Atelvia, as a U.S. district judge invalidated two key patents; the company says it's reviewing an appeal. Release

> The California Supreme Court heard arguments in a "pay-for-delay" case involving Bayer and its alleged attempts to pay several generics makers to hold off on their copies of the antibiotic Cipro. Report

> Local officials in Hillsborough County, FL, approved $2.1 million in incentives to lure Johnson & Johnson ($JNJ) and 700 new jobs to the area; the county incentives add to $7 million previously approved by the state. Report

> Pharma industry reps told the Irish health committee Oireachtas that drug prices in the country are on par with those in other European countries, amid talks about a new government pricing contract. Report

> A New York federal judge ordered Novartis ($NVS) to hand over unredacted documents by March 13 in a False Claims Act suit over alleged kickbacks to pharmacies. Report

Medical Device News

@FierceMedDev: Micro-cap TearLab gets $35M in debt to get to breakeven on dry eye test. More | Follow @FierceMedDev

@VarunSaxena2: @AdvaMedUpdate calls for more appropriate medical device reimbursement in Japan - FierceMedicalDevices. Story | Follow @VarunSaxena2

@EmilyWFierce: OpGen eyes IPO worth up to $37M for drug-resistant bacteria genetic Dx. FierceDiagnostics article | Follow @EmilyWFierce

> AdvaMed calls for 'more appropriate' medical device reimbursement in Japan. News

> Startup raises $11.7M to make laparoscopic procedures clearer. Item

Biotech News

@FierceBiotech: Biotech upstart Tricida banks $30M for its kidney drug with OrbiMed in tow. Story | Follow @FierceBiotech

@JohnCFierce: Interested in Asian biopharma? Get the latest from @FiercePharmAsia. Newsletter | Follow @JohnCFierce

@DamianFierce: Via @Reuters, it's March 5 and biopharma deal dollars have already topped 2011. Article | Follow @DamianFierce

> Surprised, stunned and supportive: Analysts assess AbbVie's $21B Pharmacyclics deal. Editor's Corner

> Summit pulls off a downsized IPO for its DMD drug. Story

Pharma Asia News

> Major policy shift on costs and safety views as China moves to lift price controls on drugs. News

> Denovo Biopharma eyes China trial of licensed Eli Lilly neuroscience drug. Article

> Indonesia gains momentum as drug firms eye second year of phased national insurance. Item

> Big Pharma bodies ask China FDA to review comparability in biosimilar approval guidelines. More

> Hutchison China MediTech eyes first modern drug approval in China next year with Eli Lilly candidate. Report

Vaccines News

> Pfizer scores new Prevenar indication in Europe. Article

> Bristol-Myers bets $1B on Bavarian Nordic cancer vaccine. News

> J&J, Merck to advance Ebola vaccines in Africa, but their fate rests in WHO's hands. Story

> With 77 layoffs, Valeant gets to work squeezing costs from Dendreon. Item

> Aduro, BMS cancer vaccine combo to start Phase II. Report

Pharma Manufacturing News

> FDA aims to disseminate drug shortage info through app. More

> Generic drugmaker snaps up Lockheed site with big expansion plans. Article

> Jordan's MS Pharma gets $30M to expand manufacturing there. Report

> FDA campaign against use of foreign-made cancer drugs rolls up another doctor. Story

> Patheon buys specialty API maker IRIX. News

And Finally... Anticholinergic drugs, which include commonly used OTC remedies such as Benadryl, might be linked to a higher risk of pneumonia. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.